DexCom, Inc. (DXCM) EVP Andrew K. Balo Sells 6,490 Shares

DexCom, Inc. (NASDAQ:DXCM) EVP Andrew K. Balo sold 6,490 shares of DexCom stock in a transaction on Wednesday, November 29th. The stock was sold at an average price of $60.00, for a total transaction of $389,400.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Andrew K. Balo also recently made the following trade(s):

  • On Monday, September 11th, Andrew K. Balo sold 3,244 shares of DexCom stock. The stock was sold at an average price of $72.27, for a total value of $234,443.88.

DexCom, Inc. (DXCM) traded down $0.95 during trading hours on Thursday, reaching $58.43. The company’s stock had a trading volume of 6,217,720 shares, compared to its average volume of 1,455,909. The company has a debt-to-equity ratio of 0.84, a current ratio of 5.86 and a quick ratio of 5.50. DexCom, Inc. has a 1 year low of $42.62 and a 1 year high of $88.80.

Several analysts recently issued reports on the stock. Canaccord Genuity restated a “buy” rating and issued a $90.00 price objective on shares of DexCom in a report on Tuesday, August 22nd. ValuEngine raised DexCom from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. BidaskClub raised DexCom from a “sell” rating to a “hold” rating in a research report on Saturday, August 19th. Barclays began coverage on DexCom in a report on Friday, September 15th. They issued an “equal weight” rating and a $76.00 price target for the company. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $90.00 price target (down from $105.00) on shares of DexCom in a report on Tuesday, August 8th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $70.69.

A number of institutional investors have recently bought and sold shares of DXCM. JPMorgan Chase & Co. grew its holdings in DexCom by 143.8% in the third quarter. JPMorgan Chase & Co. now owns 2,358,507 shares of the medical device company’s stock valued at $107,170,000 after purchasing an additional 7,738,678 shares during the last quarter. Janus Henderson Group PLC grew its holdings in DexCom by 101,699.8% in the second quarter. Janus Henderson Group PLC now owns 6,828,731 shares of the medical device company’s stock valued at $499,522,000 after purchasing an additional 6,822,023 shares during the last quarter. Winslow Capital Management LLC acquired a new stake in DexCom in the second quarter valued at $117,451,000. Brown Advisory Inc. grew its holdings in DexCom by 57.2% in the third quarter. Brown Advisory Inc. now owns 4,165,522 shares of the medical device company’s stock valued at $203,798,000 after purchasing an additional 1,515,134 shares during the last quarter. Finally, FMR LLC grew its holdings in DexCom by 9.9% in the second quarter. FMR LLC now owns 10,824,306 shares of the medical device company’s stock valued at $791,799,000 after purchasing an additional 978,898 shares during the last quarter.

COPYRIGHT VIOLATION NOTICE: “DexCom, Inc. (DXCM) EVP Andrew K. Balo Sells 6,490 Shares” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://www.americanbankingnews.com/2017/11/30/dexcom-inc-dxcm-evp-andrew-k-balo-sells-6490-shares.html.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply